Tag: Melanoma Research Alliance

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and is potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Harvard investigators at the Dana-Farber Cancer Institute.